Em recrutamento
FASE
Número Europeu 2022-502134-10-00
CAAA603C12101
Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma
Detalhes
Destaques